These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 12871204)

  • 21. Novel concepts of statin therapy for cardiovascular risk reduction in hypertension.
    Varughese GI; Patel JV; Lip GY; Varma C
    Curr Pharm Des; 2006; 12(13):1593-609. PubMed ID: 16729872
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Drug therapy for the secondary prevention of stroke in hypertensive patients: current issues and options.
    Lüders S
    Drugs; 2007; 67(7):955-63. PubMed ID: 17488141
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Does hypertension confer a prothrombotic state? Virchow's triad revisited.
    Lip GY; Blann AD
    Circulation; 2000 Jan; 101(3):218-20. PubMed ID: 10645912
    [No Abstract]   [Full Text] [Related]  

  • 24. Cancer and the prothrombotic state.
    Lip GY; Chin BS; Blann AD
    Lancet Oncol; 2002 Jan; 3(1):27-34. PubMed ID: 11908507
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of hypertension in atherosclerosis and cardiovascular disease.
    Hollander W
    Am J Cardiol; 1976 Nov; 38(6):786-800. PubMed ID: 136891
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The endothelium and atrial fibrillation. The prothrombotic state revisited.
    Freestone B; Lip GY
    Hamostaseologie; 2008 Oct; 28(4):207-12. PubMed ID: 18836646
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hypertension: renin-angiotensin-aldosterone system alterations.
    Te Riet L; van Esch JH; Roks AJ; van den Meiracker AH; Danser AH
    Circ Res; 2015 Mar; 116(6):960-75. PubMed ID: 25767283
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Platelet indexes in relation to target organ damage in high-risk hypertensive patients: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT).
    Nadar SK; Blann AD; Kamath S; Beevers DG; Lip GY
    J Am Coll Cardiol; 2004 Jul; 44(2):415-22. PubMed ID: 15261941
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effects of antihypertensive therapy on haemostatic parameters.
    Ganotakis ES; Papadakis JA; Vrentzos GE; Mikhailidis DP
    Curr Pharm Des; 2003; 9(29):2445-64. PubMed ID: 14529558
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of long-term celiprolol therapy on haemostasis in essential hypertension.
    Okrucká A; Pechán J; Kratochvílová H
    J Hum Hypertens; 1995 Sep; 9(9):773-6. PubMed ID: 8551493
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Virchow's triad revisited: the importance of soluble coagulation factors, the endothelium, and platelets.
    Blann AD; Lip GY
    Thromb Res; 2001 Feb; 101(4):321-7. PubMed ID: 11320984
    [No Abstract]   [Full Text] [Related]  

  • 32. The role of angiotensin II type 1 receptor antagonists in elderly patients with hypertension.
    Thomas GN; Chan P; Tomlinson B
    Drugs Aging; 2006; 23(2):131-55. PubMed ID: 16536636
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Retrospective studies and prospects of therapy for hypertension].
    Maisch B; Brilla C; Kruse T; Noll B; Bethge C
    Herz; 1995 Dec; 20(6):370-89. PubMed ID: 8582697
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Target organ damage in hypertension: pathophysiology and implications for drug therapy.
    Nadar SK; Tayebjee MH; Messerli F; Lip GY
    Curr Pharm Des; 2006; 12(13):1581-92. PubMed ID: 16729871
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Goals of antihypertensive therapy.
    McVeigh GE; Flack J; Grimm R
    Drugs; 1995 Feb; 49(2):161-75. PubMed ID: 7729325
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Calcium antagonists in cardiovascular disease. Clinical evidence from morbidity and mortality trials].
    Oparil S; Bakir SE
    Drugs; 2000; 59 Spec No 2():25-37. PubMed ID: 11002856
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Platelet activation in essential hypertension: implications for antiplatelet treatment.
    Gkaliagkousi E; Passacquale G; Douma S; Zamboulis C; Ferro A
    Am J Hypertens; 2010 Mar; 23(3):229-36. PubMed ID: 20094035
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Relation of thrombogenesis in systemic hypertension to angiogenesis and endothelial damage/dysfunction (a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial [ASCOT]).
    Felmeden DC; Spencer CG; Chung NA; Belgore FM; Blann AD; Beevers DG; Lip GY
    Am J Cardiol; 2003 Aug; 92(4):400-5. PubMed ID: 12914869
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cochrane in context: pharmacological interventions for hypertension in children.
    Chaturvedi S; Lipszyc DH; Licht C; Craig JC; Parekh RS
    Evid Based Child Health; 2014 Sep; 9(3):581-3. PubMed ID: 25236306
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antihypertensive drugs and fibrinolytic function.
    Fogari R; Zoppi A
    Am J Hypertens; 2006 Dec; 19(12):1293-9. PubMed ID: 17161777
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.